Urogen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research note released on Tuesday,Benzinga reports. They currently have a $33.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.29.

Urogen Pharma Stock Up 5.8%

Urogen Pharma stock opened at $17.98 on Tuesday. The firm has a fifty day moving average of $19.82 and a 200-day moving average of $20.75. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00. The firm has a market capitalization of $875.27 million, a P/E ratio of -5.62 and a beta of 1.34.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.12. The business had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. On average, research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by company insiders.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of URGN. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. State of Wyoming acquired a new position in shares of Urogen Pharma in the 3rd quarter valued at approximately $66,000. Russell Investments Group Ltd. raised its position in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of Urogen Pharma during the 3rd quarter valued at approximately $76,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.